CA2682027A1 - Modulation of tumor microenvironment - Google Patents

Modulation of tumor microenvironment Download PDF

Info

Publication number
CA2682027A1
CA2682027A1 CA002682027A CA2682027A CA2682027A1 CA 2682027 A1 CA2682027 A1 CA 2682027A1 CA 002682027 A CA002682027 A CA 002682027A CA 2682027 A CA2682027 A CA 2682027A CA 2682027 A1 CA2682027 A1 CA 2682027A1
Authority
CA
Canada
Prior art keywords
cells
antibody
interleukin
atcc deposit
malignant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002682027A
Other languages
English (en)
French (fr)
Inventor
Kandasamy Hariharan
Steffan Ho
Shabnam Tangri
Ted Yun
Arturo Molina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2682027A1 publication Critical patent/CA2682027A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002682027A 2007-03-28 2008-03-28 Modulation of tumor microenvironment Abandoned CA2682027A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90864507P 2007-03-28 2007-03-28
US60/908,645 2007-03-28
PCT/US2008/058744 WO2008119071A1 (en) 2007-03-28 2008-03-28 Modulation of tumor microenvironment

Publications (1)

Publication Number Publication Date
CA2682027A1 true CA2682027A1 (en) 2008-10-02

Family

ID=39485176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002682027A Abandoned CA2682027A1 (en) 2007-03-28 2008-03-28 Modulation of tumor microenvironment

Country Status (8)

Country Link
US (1) US20100203010A1 (enExample)
EP (1) EP2139923A1 (enExample)
JP (1) JP2010522772A (enExample)
CN (1) CN101679522A (enExample)
AU (1) AU2008230724A1 (enExample)
BR (1) BRPI0809386A2 (enExample)
CA (1) CA2682027A1 (enExample)
WO (1) WO2008119071A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6014799B2 (ja) * 2010-07-20 2016-10-26 Ｌｉｎｆｏｐｓ有限会社 解析によるミクロな腫瘍免疫挙動の顕微鏡的把握方法
EP3147297B1 (en) * 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
US9567642B2 (en) 2012-02-02 2017-02-14 Massachusetts Institute Of Technology Methods and products related to targeted cancer therapy
US8961957B2 (en) 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
US9907819B2 (en) 2012-06-27 2018-03-06 Kenichiro Hasumi Therapy and methods of introducing immature dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2015077532A1 (en) * 2013-11-21 2015-05-28 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti-tnf antibody for treatment of tumors
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CA2942245C (en) * 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3215163B1 (en) * 2014-11-06 2021-03-10 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
US20160206717A1 (en) * 2015-01-16 2016-07-21 Batu Biologics, Inc. Stimulation of immunity to endothelial cells, endothelial-like cells, and intratumor vascular channels derived from tumor tissue
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506915A (ja) * 1995-06-07 1999-06-22 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃｄ８０およびｃｄ８６発現細胞に対して特異的なイムノトキシン
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
WO2001089567A1 (en) * 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies

Also Published As

Publication number Publication date
JP2010522772A (ja) 2010-07-08
WO2008119071A1 (en) 2008-10-02
CN101679522A (zh) 2010-03-24
US20100203010A1 (en) 2010-08-12
AU2008230724A1 (en) 2008-10-02
AU2008230724A8 (en) 2009-11-26
BRPI0809386A2 (pt) 2014-09-09
EP2139923A1 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
US20100203010A1 (en) Modulation of tumor microenvironment
JP7021153B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用
AU2017201893B2 (en) Modulating agonistic tnfr antibodies
JP6875295B2 (ja) Ｔｉｇｉｔ結合物質およびその使用法
JP5665702B2 (ja) Ｎｋ細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物
JP5559695B2 (ja) 抗ｃｄ４０抗体の使用
RU2682449C2 (ru) Связывающие kir3dl2 агенты
US10494433B2 (en) Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
JP2011503098A5 (enExample)
AU2002305041B2 (en) Modulators of P-selectin glycoprotein ligand 1
JP2020510435A (ja) 抗ｇｉｔｒ抗体およびその使用方法
JP2008502322A (ja) Ｎｋ細胞活性を高めるための組成物および方法
US20100189716A1 (en) Treatment of hodgkins lymphoma
JP7165855B2 (ja) 骨髄由来抑制細胞関連疾患の予防および治療用途
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
US11186634B2 (en) Antibodies targeting tumor associated macrophages and uses thereof
CN117769435A (zh) 通过施用抗cd127剂治疗cd127阳性癌症的方法
US20240382592A1 (en) Methods for the treatment of anaplastic large cell lymphoma
US20230227565A1 (en) Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
JP7692214B2 (ja) 抗体
Simmons et al. Antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression by tumor associated macrophages
KR20260026100A (ko) 항-카텝신-d 항체
WO2019221574A1 (ko) 골수유래억제세포 관련 질환의 예방 및 치료 용도
HK40014553A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130328